SuperworthInhibikase Therapeutics EPS IKT
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$0.44
- Latest quarter, Q2 FY26
- −$0.11
- Fiscal year 2025
- −$0.49
Inhibikase Therapeutics' earnings per share was −$0.44 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.11.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.49 | n/a |
| FY2023 | −$3.63 | n/a |
| FY2022 | −$4.25 | n/a |
| FY2021 | −$5.16 | n/a |
| FY2020 | −$2.10 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.11 | n/a | −$0.44 | |
| Q1 FY26 | −$0.10 | n/a | −$0.44 | |
| Q4 FY25 | −$0.10 | n/a | −$0.49 | |
| Q3 FY25 | −$0.13 | n/a | n/a | |
| Q2 FY25 | −$0.11 | n/a | n/a | |
| Q1 FY25 | −$0.15 | n/a | n/a | |
| Q3 FY24 | −$0.65 | n/a | −$2.72 | |
| Q2 FY24 | −$0.66 | n/a | −$2.93 | |
| Q1 FY24 | −$0.73 | n/a | −$3.38 | |
| Q4 FY23 | −$0.68 | n/a | −$3.63 | |
| Q3 FY23 | −$0.86 | n/a | −$3.96 | |
| Q2 FY23 | −$1.11 | n/a | −$4.16 |
Against its peers
Companies in Biotechnology nearest Inhibikase Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IKTInhibikase Therapeutics | −$0.44 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| Peer median | $0.46 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Inhibikase Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.